San Francisco startup Composition Therapeutics is likewise focusing on an oral, at the time-each day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June when a mid-stage review showed regular weight loss of about 6% and it strategies to start A further mid-stage trial toward the end of the year—that founder and CE